NRIX
Nurix Therapeutics, Inc.
$15.64
0.00%
$1.6B
No data for this timeframe.
Vol
Market Cap$1.6B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (96%)
Inst. Holders6 funds
Inst. Value$320.3M
Inst. Activity4 buys / 3 sells
Insider Activity0B / 13S
Insider Net $-$1.4M
SEC Reports7
Press Releases2
Recent Activity
Jun 9, 2026
short_volume
Short Volume: NRIX — 59.6% short (1.9M / 3.2M)
Short: 1,890,356 | Exempt: 996 | TRF Vol: 3,169,816 | Short Ratio: 59.6% | Off-exchange volume (dark
Jun 8, 2026
SEC
Nurix Therapeutics entered into a global license and collaboration agreement with Roche to co-develop and co-commerciali
8-K — Impact 8/10
Jun 8, 2026
Press
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral
Impact 8/10
Jun 2, 2026
Insider
Ring Christine sold 3,422 shares
Chief Legal Officer @ $1.86 ($6.4K)
Jun 2, 2026
Insider
Ring Christine sold 8,148 shares
Chief Legal Officer @ $16.60 ($135.3K)
Jun 2, 2026
Insider
Ring Christine sold 3,422 shares
Chief Legal Officer @ $0.00 ($0.00)
May 5, 2026
SEC
Three C-suite insiders at Nurix Therapeutics sold a total of $415K in open-market shares over a 7-day window, with the C
CLUSTER — Impact 3/10
May 4, 2026
SEC
Three NRIX insiders (CFO, CLO, CSO) sold a combined $231K in open-market sales, a trivial 0.014% of the company's $1.7B
CLUSTER — Impact 2/10
Price Targets
$30.94
+97.8% upside
Strong Buy
Current $15.64
Low $23.00
Median $30.00
High $45.00
17 analysts
$23.00
$45.00
Analyst Ratings
8Strong Buy
14Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 9, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
| Jun 9, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Jun 8, 2026 | Jefferies | MAINTAIN | Buy → Buy |
| Jun 8, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| Jun 8, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.71 | $-0.86 — $-0.50 | -37% YoY | 15 |
| Next Q | $-0.31 ▲ +58.3% | $-0.85 — $5.69 | 70% YoY | 15 |
| Current FY | $-2.50 ▲ +15.3% | $-3.28 — $3.70 | 18% YoY | 15 |
| Next FY | $-2.82 ▲ +1.6% | $-3.49 — $-2.00 | -13% YoY | 14 |
Latest Reports
BULLISH
8-K
8/10
Nurix Therapeutics entered into a global license and collaboration agreement with Roche to co-develop and co-commerciali
Jun 8, 2026
BULLISH
Press
8/10
Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral
Jun 8, 2026
NEUTRAL
CLUSTER
3/10
Three C-suite insiders at Nurix Therapeutics sold a total of $415K in open-market shares over a 7-day window, with the C
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $112.9M | ADD |
| MORGAN STANLEY | $92.6M | DOUBLED |
| FMR LLC | $80.3M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $18.3M | ADD |
| BANK OF AMERICA CORP | $14.0M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 2, 2026 | Ring Christine | M | $6.4K |
| Jun 2, 2026 | Ring Christine | SELL | $135.3K |
| Jun 2, 2026 | Ring Christine | M | $0.00 |
| May 15, 2026 | GREGORY JULIA | A | $0.00 |
| May 15, 2026 | Baynes Roy | A | $0.00 |
6 institutional holders with $320.3M total value (16,885,043 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, FMR. Net buying activity: 4 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 5,949,512 | $112.9M | 35.2% | ADD +32.5% |
| 2 | MORGAN STANLEY | 4,881,069 | $92.6M | 28.9% | DOUBLED +115.9% |
| 3 | FMR LLC | 4,234,158 | $80.3M | 25.1% | TRIM -52.4% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 965,892 | $18.3M | 5.7% | ADD +42.4% |
| 5 | BANK OF AMERICA CORP /DE/ | 736,558 | $14.0M | 4.4% | ADD +53.1% |
| 6 | WELLS FARGO & COMPANY/MN | 117,854 | $2.2M | 0.7% | ADD +94.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 4,488,776 | 5,949,512 | +32.5% | $112.9M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 2,260,746 | 4,881,069 | +115.9% | $92.6M | 2025-Q4 |
| FMR LLC | TRIM | 8,887,537 | 4,234,158 | -52.4% | $80.3M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 481,054 | 736,558 | +53.1% | $14.0M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 60,704 | 117,854 | +94.1% | $2.2M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 62,875 | 0 | -100.0% | $0.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 184,800 | 0 | -100.0% | $0.00 | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 607,127 | 864,380 | +42.4% | $8.0M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 327,211 | 481,054 | +47.0% | $4.4M | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 1,589,040 | 362,546 | -77.2% | $3.3M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 21,900 | 184,800 | +743.8% | $1.7M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 158,724 | 62,875 | -60.4% | $581.0K | 2025-Q3 |
| MORGAN STANLEY | ADD | 1,466,860 | 2,167,121 | +47.7% | $24.7M | 2025-Q2 |
| UBS Group AG | DOUBLED | 673,147 | 1,589,040 | +136.1% | $18.1M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 257,525 | 158,724 | -38.4% | $1.8M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 59,500 | 21,900 | -63.2% | $249.4K | 2025-Q2 |
| CITADEL ADVISORS LLC | ADD | 891,019 | 1,331,158 | +49.4% | $15.8M | 2025-Q1 |
| UBS Group AG | DOUBLED | 75,113 | 673,147 | +796.2% | $8.0M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 135,084 | 257,525 | +90.6% | $3.1M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 59,500 | — | $706.9K | 2025-Q1 |
| NORGES BANK | EXIT | 318,800 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 1,557,905 | 891,019 | -42.8% | $16.8M | 2024-Q4 |
| UBS Group AG | TRIM | 102,866 | 75,113 | -27.0% | $1.4M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 246,400 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 511,720 | — | $11.5M | 2024-Q3 |
12 unique insiders with 13 transactions. Net insider value: -$1.4M ($0.00 bought, $1.4M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | Ring Christine | Chief Legal Officer | M | 3,422 | $1.86 | $6.4K |
| Jun 2, 2026 | Ring Christine | Chief Legal Officer | SELL | 8,148 | $16.60 | $135.3K |
| Jun 2, 2026 | Ring Christine | Chief Legal Officer | M | 3,422 | $0.00 | $0.00 |
| May 15, 2026 | GREGORY JULIA P | Director | A | 31,250 | $0.00 | $0.00 |
| May 15, 2026 | Baynes Roy D. | Director | A | 31,250 | $0.00 | $0.00 |
| May 15, 2026 | DANSEY ROGER D | Director | A | 31,250 | $0.00 | $0.00 |
| May 15, 2026 | Kapur Anil | Director | A | 31,250 | $0.00 | $0.00 |
| May 15, 2026 | Lacey David L. | Director | A | 31,250 | $0.00 | $0.00 |
| May 15, 2026 | Reinsdorf Judith A | Director | A | 31,250 | $0.00 | $0.00 |
| May 15, 2026 | Saltzman Edward C | Director | A | 31,250 | $0.00 | $0.00 |
| May 15, 2026 | Silva Paul M | Director | A | 31,250 | $0.00 | $0.00 |
| May 5, 2026 | van Houte Hans | Chief Financial Officer | SELL | 13,473 | $16.58 | $223.3K |
| May 4, 2026 | Ring Christine | Chief Legal Officer | SELL | 8,148 | $16.96 | $138.2K |
| May 1, 2026 | Ring Christine | Chief Legal Officer | SELL | 5,394 | $16.76 | $90.4K |
| Apr 30, 2026 | Hansen Gwenn | Chief Scientific Officer | M | 2,000 | $0.00 | $0.00 |
| Apr 30, 2026 | Hansen Gwenn | Chief Scientific Officer | SELL | 3,214 | $16.65 | $53.5K |
| Apr 30, 2026 | Hansen Gwenn | Chief Scientific Officer | M | 2,000 | $0.00 | $0.00 |
| Apr 30, 2026 | Ring Christine | Chief Legal Officer | M | 2,000 | $0.00 | $0.00 |
| Apr 30, 2026 | Ring Christine | Chief Legal Officer | SELL | 3,214 | $16.65 | $53.5K |
| Apr 30, 2026 | Ring Christine | Chief Legal Officer | M | 2,000 | $0.00 | $0.00 |
| Apr 30, 2026 | van Houte Hans | Chief Financial Officer | M | 2,000 | $0.00 | $0.00 |
| Apr 30, 2026 | van Houte Hans | Chief Financial Officer | M | 2,000 | $0.00 | $0.00 |
| Apr 30, 2026 | van Houte Hans | Chief Financial Officer | SELL | 2,388 | $16.65 | $39.7K |
| Apr 2, 2026 | Ring Christine | Chief Legal Officer | SELL | 8,148 | $15.24 | $124.1K |
| Mar 2, 2026 | Ring Christine | Chief Legal Officer | SELL | 8,148 | $15.44 | $125.8K |
| Feb 10, 2026 | van Houte Hans | Chief Financial Officer | A | 42,875 | $0.00 | $0.00 |
| Feb 10, 2026 | van Houte Hans | Chief Financial Officer | A | 93,750 | $0.00 | $0.00 |
| Feb 10, 2026 | Ring Christine | Chief Legal Officer | A | 42,875 | $0.00 | $0.00 |
| Feb 10, 2026 | Ring Christine | Chief Legal Officer | A | 93,750 | $0.00 | $0.00 |
| Feb 10, 2026 | Hansen Gwenn | Chief Scientific Officer | A | 42,875 | $0.00 | $0.00 |
| Feb 10, 2026 | Hansen Gwenn | Chief Scientific Officer | A | 93,750 | $0.00 | $0.00 |
| Feb 10, 2026 | SANDS ARTHUR T | President, CEO | A | 562,500 | $0.00 | $0.00 |
| Feb 9, 2026 | Ring Christine | Chief Legal Officer | SELL | 14,261 | $16.66 | $237.6K |
| Feb 3, 2026 | Hansen Gwenn | Chief Scientific Officer | M | 31,333 | $0.8400 | $26.3K |
| Feb 3, 2026 | Hansen Gwenn | Chief Scientific Officer | M | 31,333 | $0.00 | $0.00 |
| Jan 30, 2026 | van Houte Hans | Chief Financial Officer | M | 2,887 | $0.00 | $0.00 |
| Jan 30, 2026 | van Houte Hans | Chief Financial Officer | SELL | 3,588 | $16.58 | $59.5K |
| Jan 30, 2026 | van Houte Hans | Chief Financial Officer | M | 2,887 | $0.00 | $0.00 |
| Jan 30, 2026 | Ring Christine | Chief Legal Officer | M | 1,925 | $0.00 | $0.00 |
| Jan 30, 2026 | Ring Christine | Chief Legal Officer | SELL | 4,333 | $16.58 | $71.9K |
| Jan 30, 2026 | Ring Christine | Chief Legal Officer | M | 1,925 | $0.00 | $0.00 |
| Jan 30, 2026 | Hansen Gwenn | Chief Scientific Officer | M | 3,207 | $0.00 | $0.00 |
| Jan 30, 2026 | Hansen Gwenn | Chief Scientific Officer | SELL | 4,797 | $16.58 | $79.5K |
| Jan 30, 2026 | Hansen Gwenn | Chief Scientific Officer | M | 3,207 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 4 neutral. Avg impact: 4.3/10.
BULLISH
8-K
8/10
Nurix Therapeutics entered into a global license and collaboration agreement with Roche to co-develo
Jun 8, 2026
NEUTRAL
CLUSTER
3/10
Three C-suite insiders at Nurix Therapeutics sold a total of $415K in open-market shares over a 7-da
May 5, 2026
NEUTRAL
CLUSTER
2/10
Three NRIX insiders (CFO, CLO, CSO) sold a combined $231K in open-market sales, a trivial 0.014% of
May 4, 2026
NEUTRAL
CLUSTER
2/10
Three C-suite insiders at Nurix Therapeutics (NRIX) sold a total of ~$184K in open-market shares ove
May 1, 2026
NEUTRAL
CLUSTER
2/10
Two C-suite insiders at Nurix Therapeutics sold a combined $107K in open-market shares on April 30,
Apr 30, 2026
BEARISH
PRESS-RELEASE
7/10
Nurix Therapeutics (NRIX) reported Q1 2026 financial results with revenue of $6.3M, down 66% YoY, an
Apr 21, 2026
BEARISH
8-K
6/10
Nurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million, down from $18.5
Apr 8, 2026
Current analyst consensus: Strong Buy (96% buy). Based on 23 analysts: 8 strong buy, 14 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$30.94 mean target
+97.8% upside
Strong Buy (1.41)
$23.00 Low
$45.00 High
| Metric | Value |
|---|---|
| Current Price | $15.64 |
| Target Low | $23.00 |
| Target Mean | $30.94 |
| Target Median | $30.00 |
| Target High | $45.00 |
| # Analysts | 17 |
| Recommendation | Strong Buy (1.41) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-05-31 |
$-0.71 | $-0.86 | $-0.50 | -37.4% | +0.0% | 10↑ 0↓ | $0.0B | -63.8% | 15 |
| Next Q 2026-08-31 |
$-0.31 | $-0.85 | $5.69 | 70.1% | +58.3% | 10↑ 1↓ | $0.1B | 648.8% | 15 |
| Current FY 2026-11-30 |
$-2.50 | $-3.28 | $3.70 | 18.2% | +15.3% | 9↑ 5↓ | $0.1B | 63.9% | 15 |
| Next FY 2027-11-30 |
$-2.82 | $-3.49 | $-2.00 | -12.9% | +1.6% | 9↑ 2↓ | $0.1B | -42.4% | 14 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.715 | |
| 7d ago | $-0.715 | |
| 30d ago | $-0.715 | |
| 60d ago | $-0.734 | +0.020 |
| 90d ago | $-0.792 | +0.077 |
10 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 9, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jun 9, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Jun 8, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Jun 8, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jun 8, 2026 | Needham | MAINTAIN | Buy | Buy |
| May 18, 2026 | BTIG | REITERATE | Buy | Buy |
| Apr 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 23, 2026 | Needham | REITERATE | Buy | Buy |
| Apr 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 9, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Apr 8, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 24, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 29, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 29, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 29, 2026 | Stifel | MAINTAIN | Buy | Buy |
| Jan 29, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Jan 29, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 29, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 29, 2026 | Needham | REITERATE | Buy | Buy |
| Jan 8, 2026 | Morgan Stanley | UPGRADE | Equal-Weight | Overweight |
| Dec 16, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 8 | 14 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 8 | 14 | 1 | 0 | 0 | 96% | |
| Apr 1, 2026 | 8 | 14 | 1 | 0 | 0 | 96% | |
| Mar 1, 2026 | 8 | 14 | 1 | 0 | 0 | 96% | |
| Feb 1, 2026 | 8 | 14 | 1 | 0 | 0 | 96% | |
| Jan 1, 2026 | 8 | 13 | 2 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: NRIX — 59.6% short (1.9M / 3.2M)
Short: 1,890,356 | Exempt: 996 | TRF Vol: 3,169,816 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
contract
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
<p align="center"><em>Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted th
Jun 8, 2026
short_volume
Short Volume: NRIX — 59.2% short (4.5M / 7.5M)
Short: 4,460,349 | Exempt: 69,893 | TRF Vol: 7,534,436 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: NRIX — 56.8% short (0.3M / 0.6M)
Short: 324,375 | Exempt: 11 | TRF Vol: 570,898 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: NRIX — 78.1% short (1.0M / 1.2M)
Short: 952,609 | Exempt: 108 | TRF Vol: 1,219,284 | Short Ratio: 78.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
other
Nurix Therapeutics to Participate in Upcoming Investor Conferences
<p>BRISBANE, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on
Apr 22, 2026
fda
Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
<p align="center">Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs</p>
Apr 15, 2026
short_interest
FTD: NRIX — 36,456 shares ($0.6M) failed to deliver
Settlement: 20260415, Price: $16.30, FTD Value: $594,232.8, NURIX THERAPEUTICS INC
Apr 8, 2026
earnings
Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
<p align="center"><em>Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic ly
Apr 6, 2026
earnings_calendar
NRIX Q1 2026 Earnings Scheduled — 2026-04-06
Mar 25, 2026
short_volume
Short Volume: NRIX — 56.2% short (0.6M / 1.1M)
Short: 618,291 | Exempt: 0 | TRF Vol: 1,100,157 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Mar 23, 2026
routine
Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting
<p>BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused